Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29612139 | 1.00 | CYP3A4 (0.58) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL10339706 | 0.87 | CYP3A4 (0.56) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL30977128 | 0.85 | CYP3A4 (0.59) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL4397386 | 0.85 | TPMT (0.58) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL4608589 | 0.84 | CYP3A4 (0.56) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL10717910 | 0.81 | ALOX5 (0.50) | — | |
| SCHEMBL4220772 | 0.80 | FFAR1 (0.52) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL27613224 | 0.80 | HMGCR (0.57) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL10498389 | 0.79 | CYP3A4 (0.55) | CYP3A4USP2MAPK1SMN1; SMN2HTT | |
| SCHEMBL9612313 | 0.79 | TUBB1 (0.44) | CYP3A4USP2MAPK1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994460-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | Indiana University Research and Technology Corporation (US) | 2016-03-16 | — | — | EP | claimed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | claimed |
| WO-2014182695-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-11-13 | — | — | WO | claimed |
| CN-115992105-B | Apigenin 6-hydroxylase protein, and coding gene and application thereof | 中国中医科学院中药研究所 | 2025-04-29 | — | — | CN | disclosed |
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023127291-A1 | METHOD FOR PRODUCING DEMETHYLNOBILETIN | 花王株式会社 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023127291-A1 | METHOD FOR PRODUCING DEMETHYLNOBILETIN | 花王株式会社 | 2023-07-06 | — | — | WO | disclosed |
| CN-115992105-A | Apigenin 6-hydroxylase protein, and coding gene and application thereof | 中国中医科学院中药研究所 | 2023-04-21 | — | — | CN | disclosed |
| WO-2022123573-A1 | COMPOUNDS FOR TREATING EYE DISEASES AND DISORDERS | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2022-06-16 | — | — | WO | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| WO-2014182695-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-11-13 | — | — | WO | disclosed |
| US-8138165-B2 | Chromones and chromone derivatives and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138165-B2 | Chromones and chromone derivatives and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138165-B2 | Chromones and chromone derivatives and uses thereof | JENKEN BIOSCIENCES, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
| EP-2097420-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Products Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065508-A1 | SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142211-A1 | Chromones and chromone derivatives and uses thereof | PROC, HMGB1, PYCARD | CYP3A4 89/4885USP2 4750/4885MAPK1 515/4885 |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP3A4 3509/4885USP2 4671/4885MAPK1 3410/4885 |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | CYP3A4 1414/4885USP2 3839/4885MAPK1 1428/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | CYP3A4 3509/4885USP2 4671/4885MAPK1 3410/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | CYP3A4 3509/4885USP2 4671/4885MAPK1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.